Jove
Visualize
Contact Us

Related Experiment Videos

Juvenile dermatomyositis update.

Carol B Lindsley1

  • 1Department of Pediatrics, University of Kansas Medical Center, Kansas City, KS 66160-7330, USA. clindsle@kumc.edu

Current Rheumatology Reports
|August 12, 2006
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

2016 American College of Rheumatology/European League Against Rheumatism Criteria for Minimal, Moderate, and Major Clinical Response in Juvenile Dermatomyositis: An International Myositis Assessment and Clinical Studies Group/Paediatric Rheumatology International Trials Organisation Collaborative Initiative.

Annals of the rheumatic diseases·2017
Same author

2016 American College of Rheumatology/European League Against Rheumatism Criteria for Minimal, Moderate, and Major Clinical Response in Juvenile Dermatomyositis: An International Myositis Assessment and Clinical Studies Group/Paediatric Rheumatology International Trials Organisation Collaborative Initiative.

Arthritis & rheumatology (Hoboken, N.J.)·2017
Same author

Policy challenges for the pediatric rheumatology workforce.

Pediatric rheumatology online journal·2012
Same author

Treatment approaches to juvenile dermatomyositis (JDM) across North America: The Childhood Arthritis and Rheumatology Research Alliance (CARRA) JDM Treatment Survey.

The Journal of rheumatology·2010
Same author

Validation of manual muscle testing and a subset of eight muscles for adult and juvenile idiopathic inflammatory myopathies.

Arthritis care & research·2010
Same author

Protocols for the initial treatment of moderately severe juvenile dermatomyositis: results of a Children's Arthritis and Rheumatology Research Alliance Consensus Conference.

Arthritis care & research·2010
Same journal

Type I Interferonopathies: Fifteen Years On, From Concept to Therapeutic Perspectives.

Current rheumatology reports·2026
Same journal

Intensive Care Management of ANCA-associated Vasculitides: a Narrative Review.

Current rheumatology reports·2026
Same journal

The Role of Musculoskeletal Ultrasound in Psoriatic Arthritis: From Preclinical Detection to Treatment Monitoring.

Current rheumatology reports·2026
Same journal

Correction to: Is Gout and Autoinflammatory Disease?

Current rheumatology reports·2026
Same journal

Risks and Management of Glucocorticoid Therapy for Patients with Rheumatic Disease Having Surgery.

Current rheumatology reports·2026
Same journal

Perioperative Management Considerations for Patients with Systemic Lupus Erythematosus.

Current rheumatology reports·2026
See all related articles
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Juvenile dermatomyositis may follow infections, with distinct skin and muscle damage pathways. Methotrexate with corticosteroids aids growth in affected children.

Area of Science:

  • Pediatric rheumatology
  • Autoimmune diseases
  • Dermatology

Background:

  • Juvenile dermatomyositis (JDM) is a rare autoimmune disease affecting children.
  • Understanding JDM's triggers, pathophysiology, and treatment is crucial for improving patient outcomes.

Purpose of the Study:

  • To summarize recent findings on juvenile dermatomyositis.
  • To highlight potential infection triggers, distinct disease mechanisms, and effective therapeutic strategies.

Main Methods:

  • Review of recent studies on juvenile dermatomyositis.
  • Analysis of clinical presentation, pathophysiology, laboratory markers, and treatment outcomes.

Main Results:

  • Most children with JDM exhibit infection-like symptoms before disease onset.

Related Experiment Videos

  • Skin and muscle damage in JDM involve separate pathophysiological processes.
  • Urinary muscle metabolites show potential as diagnostic markers.
  • First-line therapy with methotrexate and corticosteroids promotes height velocity and limits BMI increase in JDM patients.

    • Conclusions:

    • Infection may precede JDM onset, with unique skin and muscle pathologies.
    • Metabolite analysis and combination therapy offer promising avenues for JDM management.